Friday Mar 28
FDA Agrees to Review Drug - "Device Combo for Migraine
The FDA has accepted a new drug application for AVP-825, an investigational drug-device combination product for the acute treatment of migraine.
Wed Mar 26, 2014
Avanir Pharmaceuticals Announces Acceptance of New Drug...
Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the company's New Drug Application of AVP-825, its innovative Breath Powereda investigational drug-device combination product for the acute treatment of migraine.
Wed Mar 12, 2014
Double-Blind, Placebo-Controlled, Crossover Study of...
Objective: Published studies of triptans in acute migraine have shown relatively disappointing 2-hour pain-free rates, ranging from 18% to 58%, with 2- to 24-hour sustained pain-free rates from 17% to 25%.
Tue Mar 11, 2014
U.S. drug regulator approves headband device to prevent migraines
The U.S. Food and Drug Administration said on Tuesday it approved a nerve-stimulating device to prevent migraines that is worn as a band across the forehead.
Tue Mar 04, 2014
The Motley Fool
Can Allergan's Growth Continue?
Allergan's pipeline is somewhat more limited than an investor might normally prefer, but the company has been active in pursuing follow-on indications for existing drugs and has had a higher than normal "hit" rate for its pipeline.